ZKY 011
Alternative Names: ZKY-011Latest Information Update: 21 Dec 2020
At a glance
- Originator China Ophthalmology Focus
- Developer Lee's Pharmaceutical; Zhaoke Ophthalmology Limited
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Eye disorders
Most Recent Events
- 11 Dec 2020 Preregistration for Eye disorders in China (unspecified route), prior to December 2020 (Lee's pharmaceutical pipeline, December 2020)
- 11 Dec 2020 China Ophthalmology Focus Limited submits application to regulatory authority for Eye disorders, prior to December 2020 (Lee's Pharmaceutical pipeline, December 2020)